Physician profile
Rosemary A Bates
NPI 1124007257
$845.46
in general payments reported to CMS, 2019-2025
16 companies · $53.77 in 2025
The $53.77 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $135 · 2020: $98.47 · 2021: $98.77 · 2022: $92.89 · 2023: $150 · 2024: $217 · 2025: $53.77.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $421.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $420.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $187.76 | 2021-2025 | Ubrelvy |
| Heartflow, INC. | $146.01 | 2024 | |
| Novo Nordisk INC | $105.20 | 2019-2022 | |
| Currax Pharmaceuticals LLC | $73.80 | 2020-2022 | |
| Glaxosmithkline, LLC. | $58.80 | 2023-2024 | Shingrix, Arexvy |
| Pfizer INC. | $54.56 | 2023-2024 | |
| Si-Bone, INC. | $40.95 | 2019-2020 | |
| Lilly USA, LLC | $38.62 | 2020-2024 | Jardiance |
| Eisai INC. | $28.40 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $25.34 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.95 | 2025 | Jardiance |
| Astellas Pharma US INC | $16.52 | 2025 | Veozah |
| Galderma Laboratories, L.P. | $14.40 | 2024 | |
| Allergan, INC. | $14.27 | 2020 | |
| Merck Sharp & Dohme LLC | $13.02 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Therapeuticsmd, INC. | $10.86 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rosemary Bates listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.